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doi:10.1016/j.kjms.2011.10.030Abstract This study investigated the differences in clinical and laboratory features as well as
treatment response in 70 outpatients withmacroprolactinemia andmonomeric hyperprolactine-
mia treated with dopamine agonists. After precipitation of the patients’ serum samples with
poly-ethylene-glycol (PEG), serum prolactin (PRL) levels were measured. We also measured
serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol for
women and testosterone for men. Clinical symptoms and signs were recorded. All patients
received brainmagnetic resonance imaging (MRI). After excluding patients withmacroadenoma,
66 patients were treated with the dopamine agonist cabergoline. After 1 year, the clinical
responses to cabergoline were recorded and PRL levels measured. Of the initial 70 patients with
hyperprolactinemia, 15 patients (21.4%) were found to have macroprolactinemia, while the rest
had monomeric hyperprolactinemia. The two groups did not differ with regard to galactorrhea,
menstrual disturbances or impotence. There were no significant group differences in serum LH,
FSH, estradiol or testosterone levels. Patients with macroprolactinemia, however, had a signifi-
cantly lower infertility rate than thosewith true hyperprolactinemia (6.7% vs. 32.7%, pZ 0.005).
A greater percentage ofmacroprolactinemic patients hadnormalMRI pituitary images than those
with hyperprolactinemia (73.3% vs. 34.5%, pZ 0.029). Compared to thosewith true hyperprolac-
tinemia, patients with macroprolactinemia were found to have no significant changes in clinical
features and PRL levels after 1 year of cabergoline therapy (after PEG precipitation, pre- and
post-PRL levels: 59.3 100.2 to 13.8 9.5 ng/mL vs. 6.1 5.3 to 5.1 4.3 ng/mL, pZ 0.002).
In conclusion, while macroprolactinemia is a common cause of hyperprolactinemia, many clinical
and laboratory features cannot be used reliably to differentiate macroprolactinemia from true
hyperprolactinemia. Routine screening for all hyperprolactinemic sera with PEG might prevent
the unnecessary use of image studies andmedical treatments for peoplewith hyperprolactinemia.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.of Internal Medicine, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Region, Kaohsiung
t.net (C.-J. Hsieh).
vier Taiwan LLC. All rights reserved.
Macroprolactinemia 95Introduction serum globulin concentrations, such as renal insufficiencyHyperprolactinemia can be caused by physiological or
pathological conditions that lead to the hypersecretion of
PRL in the lactotroph cells. Physiological conditions include
pregnancy and lactation, while pathological conditions
may include a hypothalamic tumor, lactotroph adenoma,
the use of dopamine-2 receptor antagonist drugs or hypo-
thyroidism [1,2]. Hyperprolactinemia is also the most
common abnormality of the hypothalamicpituitary axis
and the most frequent manifestation of functional pitui-
tary adenomas [1]. It has been associated with the
suppression of gonadotropin secretion and decreases in sex
hormones in men and women, resulting in sexual
dysfunction, such as aspermatogenesis in men and anov-
ulation in women, both of which will prompt physicians to
measure prolactin (PRL) levels to confirm suspicions of this
disease.
The detection of serum PRL may be difficult when there
is interference between macroprolactin and PRL assays
[3,4]. Human serum PRL appears in three major molecular
forms: the biologically and immunologically active mono-
meric PRL (little PRL, 23 kDa, 8595%), the biologically
inactive dimeric PRL (big PRL, 5060 kDa, 515%), and
low activity tetrameric PRL (big big PRL, 150170 kDa,
<1%) [5]. Macroprolactin, however, is a complex of dimer-
ic and tetrameric PRL [6,7]. While macroprolactinemia
is defined as a preponderance of macroprolactin in
hyperprolactinemic sera [8], its clinical significance is
controversial. In most studies [8e10], patients with mac-
roprolactinemia always have normal menstruation cycles,
spontaneous conception and mild galactorrhea. One study
suggests that a misdiagnosis of macroprolactinemia as
monomeric hyperprolactinemia might lead to unnecessary
and unhelpful pituitary exploration and treatment [11].
Some previous studies finding bioactivity in vivo, however,
suggest that macroprolactinemia could cause galactorrhea,
menstrual irregularities, infertility and erectile dysfunction
[2,12,13]. It has also been suggested that treatment with
dopamine agonists (DAs) could lower the serum macro-
prolactin levels [2,12].
The aim of this study was to investigate the prevalence
of macroprolactinemia in people from Taiwan, differen-
tiate the clinical and laboratory features of macro-
prolactinemia and monomeric hyperprolactinemia, and to
evaluate the differences in these two groups’ responses to
treatment with a DA.Methods
Participants
Between October 2009 and February 2011, we enrolled
70 patients (61 women and nine men; aged 39 10 years)
form our outpatient clinics at the Endocrinology, Neuro-
surgery and Gynecology Department in Kaohsiung Chang
Gung Memorial Hospital (CGMH) who were diagnosed as
having hyperprolactinemia (PRL serum level 18.0 ng/mL
for men and 7.0 ng/mL for women). We excluded patients
with other major diseases that could induce elevation of(creatinine >1.4 mg/dl), adrenal insufficiency, primary
hypothyroidism, polycystic ovary syndrome, IgG myeloma
and polyclonal hypergammaglobulinemia due to HIV infec-
tion. We also excluded any patients who were pregnant,
breast feeding or taking a drug that could lead to an
increase PRL levels. Poly-ethylene-glycol (PEG) was used to
analyze all serum samples. We also measured serum levels
of luteinizing hormone (LH), follicle stimulating hormone
(FSH), estradiol in women and testosterone in men.
All patients underwent magnetic resonance imaging
(MRI) studies. We excluded the patients with macro-
adenoma found by MRI (tumor diameter >1.0 cm) because
they would probably receive surgery later on. Of the
patients with monomeric hyperprolactinemia, four had
macroadenomas. No patients diagnosed with macro-
prolactinemia had a tumor. After exclusion, we were left
with 66 patients that we could treat with a DA. These
participants consisted of 58 women and eight men (aged
38.2 10.4 years). Each received cabergoline (1 mg/week)
in tablet form. Drug compliance was calculated by the
number of surplus tablets they returned to us at the end of
each 3-month prescription period. No patient to returned
>10% of the prescribed doses. After 12 months, we
measured their serum PRL levels and evaluated changes in
their clinical features. The evaluation was performed by
the same physicians that they had initially visited. The
clinical features analyzed in this study were oligomenor-
rhea, amenorrhea, galactorrhea, impotence and infertility.
All the clinical features were confirmed by a gynecologist
and urologist, and met the criteria for diagnosis.
This study was conducted according to the guidelines
outlined in the declaration of Helsinki and the protocol
for this study was approved by the CGMH Ethics Committee.Tests
Serum estradiol, testosterone, LH and FSH were measured
using a commercially-available immunoradiometric assay
(125I IRMA, IMMUNOTECH, Beckman Coulter Company, USA),
as was PRL (125I IRMA, IMMUNOTECH, Beckman Coulter
Company), with a reference range of 1.018.0 ng/ml for
men and 1.027.0 ng/ml for women. The low, normal and
high ranges for the coefficient of variation (CV) and intra-
assay CV were 8.0%, 6.7% and 6.2%, and 1.6%, 2.8% and
2.8%, respectively.
After PEG precipitation, we measured the presence of
macroprolactin in hyperprolactinemic sera using a PRL assay.
To do this, 250 uL of serum was mixed with an equal volume
of PEG (250 g/L, molecular mass 6000 kDa, product no.
528877, Merck Ltd, Darmstadt, Germany) and incubated for
10 minutes at room temperature. The suspension was clari-
fied by centrifugation at 1800 g for 30 minutes. The super-
natant was analyzed for prolactin. Macroprolactinemia was
determined by measuring the PRL serum level before and
after PEG precipitation. As in previous studies [14,15],
macroprolactinemia was defined as having a PRL recovery of
40% after PEG precipitation and monomeric (true) hyper-
prolactinemia was defined as having a recovery of >40%.
Every sample was assayed three times and an average value
was assigned.
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Differences between the groups were analyzed using a non-
parametric Wilcoxon test. Differences between time points
in treatment were calculated using repeated measures of
the general linear model. All data are reported as mean-
s standard deviation. A probability value of <0.05 was
regarded to be significant. All statistical operations were
performed using the Statistical Package for Social Science
program (SPSS for Windows, Version 11.5; SPSS, Chicago).
Results
Changes in PRL after PEG precipitation
As can be seen in Table 1, which gives a summary of
different variables between macroprolactinemia and
monomeric hyperprolactinemia after PEG precipitation, 15
of the 70 patients (21.4%) with high PRL levels were found
to have macroprolactinemia. There was no difference in
age or gender between the two groups. After PEG precipi-
tation, all samples of hyperprolactinemic sera had
decreases in PRL, though the PRL level in most of the
macroprolactinemic patients remained within normal
limits. The mean serum prolactin levels after PEG precipi-
tation in macroprolactinemic patients and true hyper-
prolactinemic patients were 6.1 5.3 ng/mL and
62.2 160.2 ng/mL, respectively (pZ 0.003).
Clinical manifestations and laboratory features
Table 1 shows that macroprolactinemia and monomeric
hyperprolactinemia did not differ with regard to the
following clinical features:Table 1 The clinical characteristics of patients with macroprol
Characteristics Macroprolact
(nZ 15
Sex ratio (F/M) (12/3)
Age (yr) 37.5 11.
Basal PRL (ng/mL) 63.3 59.
(22.5261
Post PEG PRL (ng/mL) 6.1 5.3
(1.924.7
Normal MRI 11 (73.3%)
Galactorrhea 3 (20%)
Menstrual disorder (oligo- or amenorrhea) 8 (66.7%)
Impotence (men) 3 (100%)
Infertility 1 (6.7%)
FSH (mIU/ml)b 9.13 6.5
LH (pg/ml)b 13.38 13
Estradiol (pg/ml)c 28.23 12
Testosterone (ng/ml)d 2.48 4.4
Key: MRIZmagnetic resonance imaging, NSZ not significant, PEGZ
a range of prolactin serum level.
b follicle-stimulating hormone and luteinizing for both sexes.
c estradiol for women.
d testosterone for men. galactorrhea (20% vs. 31%);
 menstrual disturbances (oligomenorrhea or amenor-
rhea, 66.7% vs. 77.6%); and
 impotence (100% of men in both groups).
Patients with macroprolactinemia had a significantly
lower infertility rate than those with monomeric hyper-
prolactinemia (6.7% vs. 32.7%, pZ 0.005). Laboratory work
showed no significant group differences in serum FSH
(9.13 6.54 vs. 9.77 7.06 mIU/ml), LH (13.38 13.87 vs.
14.87 9.92 pg/ml), estradiol (in women, 28.23 12.12 vs.
30.46 11.22 pg/ml) and testosterone (in men, 2.48 4.49
vs. 2.39 3.17 ng/ml).
Image findings
MRI findings revealed that four patients in the macro-
prolactinemic group (26.7%) had pituitary lesions. Three of
these patients had a microadenoma and one had empty
sella lesions. Four of the 55 monomeric hyperprolactinemic
patients (7%, three women and one man) had macro-
adenomas, 32 (58.2%) had microadenomas, and 19 (34.5%)
were not found to have any pituitary lesions. A greater
percentage of macroprolactinemic subjects had normal
pituitary images (73.3% vs. 34.5%, pZ 0.029).
Treatment response
This study found no apparent change in clinical features
(including infertility) in the macroprolactinemic group, but
there were changes in the symptoms experienced by the
patients with monomeric hyperprolactinemia patients.
After 1 year, these patients experienced a reduction in
galactorrhea (from 31.4% to 2.0%), menstrual disturbances






















4 9.77 7.06 NS
.87 14.87 9.92 NS
.12 30.46 11.22 NS
9 2.39 3.17 NS
poly-ethylene-glycol, PRLZ prolactin.
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shown in Table 2, were significant (p< 0.001). The PRL
levels decreased to within the normal range in all patients
with monomeric hyperprolactinemia, with basal levels
ranging from 130.5 210.6 ng/mL to 15.2 10.2 ng/mL vs.
post-PEG levels from 59.3 100.2 ng/mL to 13.8 9.5 ng/
mL (p< 0.001). There were no clear improvements,
however, in the macroprolactinemic patients in whom basal
levels ranged from 63.3 59.2 ng/mL to 60.4 50.8 ng/mL
and post-PEG levels ranged from 6.1 5.3 ng/mL to
5.1 4.3 ng/mL. Compared to the patients with monomeric
hyperprolactinemia, those with macroprolactinemia had
higher rate of galactorrhea (13.3% vs. 2.0%, p< 0.001),
menstrual disturbances (50.0% vs. 6.5%, p< 0.001), impo-
tence (in men, 100% vs. 20%, p< 0.001) and infertility (6.7%
to 3.9%, pZ 0.03), even after treatment with cabergoline.Discussion
Due to no specific symptoms and signs, macroprolactinemia
may lead to unnecessary pituitary exploration and treat-
ment and has not attracted much attention since the first
case of macroprolactinemia was reported in 1981 [16]. This
may be due to differences in the cut-off values of PRL
recovery after PEG precipitation, race, and equivocal
clinical symptoms. This study, the first of its kind to be
performed in Taiwan, found the prevalence of macro-
prolactinemia to be 21.4% in our hyperprolactinemic
patients, which is consistent with the findings of previous
investigations in other countries, the ratio being between
10% and 46% [2,3,12,14,17]. In our patients, by comparison
with gel-filtration chromatography, the gold standard
method, a PRL recovery 40% was defined as macro-
prolactinemia. This is considered a reliable diagnostic
criterion. As in previous studies [14,15], PRL recovery >40%
was classified as true or monomeric hyperprolactinemia. In
some studies [18,19], PRL recovery of between 40% and 50%
necessitated gel filtration chromatography to confirm the
presence of macroprolactin. However, in our study, none of
the patients enrolled had a recovery rate within this band,
so we did not need to carry out such time-consuming and
expensive tests.Table 2 A comparison of changes in clinical characteristics
hyperprolactinemia after 1 year of dopamine agonist therapy.
Characteristics Macroprolactinemia
(nZ 15, F/MZ 12/3)
Before treatment After treatme
Basal PRL (ng/mL) 63.3 59.2 60.4 50.8
Post-PEG PRL (ng/mL) 6.1 5.3 5.1 4.3
Galactorrhea 3 (20%) 2 (13.3%)
Menstrual disorder 8 (66.7%) 6 (50%)
Impotence (men) 3 (100%) 3 (100%)
Infertility 1 (6.7%) 1 (6.7%)
Differences between the treatment time points were calculated usin
*tests of intrasubject contrasts in the group after 1 year of treatmen
Key: PEGZ poly-ethylene-glycol, PRLZ prolactin.
a tests of intersubject effects.For many years, macroprolactinemia was regarded to be
asymptomatic among hyperprolactinemic patients [8,9]. In
recent studies [2,12,13] as well as ours in investigation,
however, the same symptoms have been to found to be
as common in macroprolactinemia as in true hyper-
prolactinemia. Such symptoms were non-specific. About half
of our macroprolactinemia patients were symptomatic. The
groups did not differ with regard to the frequency of galac-
torrhea, menstrual disturbances or impotence. Infertility was
significantly more prevalent in the patients with true hyper-
prolactinemia, and this may be the only thing distinguishing
cases of macroprolactinemia from true hyperprolactinemia.
Despite this, a diagnosis of infertility is more difficult to
render and requires a longer observation time than other
symptoms, so it may not serve as a reliable or practical
diagnostic clue. The overlap of clinical features therefore still
prohibits us from being able to use symptoms to distinguish
between macroprolactinemia and true hyperprolactinemia.
Due to the reduced ability of macroprolactin unable to
suppress the hypothalamic pituitarygonadal axis, levels
of LH have previously been reported to be significantly
higher in macroprolactinemic patients [20]. As with de
Soa´rez et al. [21], we found no significant difference in
serum LH and FSH levels, estradiol levels in women or
testosterone levels in men between the two groups. The
results of our study may be confounded, however, by the
variable biological activity ofmacroprolactin or the pulsatile
secretion of these hormones. A number of studies on
macroprolactin biological activity have been performed
[22e25]. Few have revealed similar in vitro activity as true
hyperprolactinemia, but most have shown less activity
[23,24]. It has been postulated that, although macro-
prolactin has the ability to present monomeric prolactin-like
activity in vitro, its bioavailability would be negligible
in vivo due to its high molecular weight [26,27]. Macro-
prolactin should be confined to the vascular system but
several studies using a Nb2 rat lymphoma cell bioassay have
shown macroprolactin to have variable biological activity
in vivo [8,28,29]. Another study has suggested that this
might be due to macroprolactin’s ability to intermittently
dissociate from IgG [28]. This finding is consistent with our
data, showing the overlap of clinical and biochemical
features of the two entities.between patients with macroprolactinemia and monomeric
True hyperprolactinemia
(nZ 51, F/MZ 46/5)
p-valuea
nt Before treatment After treatment
130.5 210.6 15.2 10.2* 0.004
59.3 100.2 13.8 9.5* 0.002
16 (31.4%) 1 (2.0%)* <0.001
37 (80.4%) 3 (6.5%)* <0.001
5 (100%) 1 (20%)* <0.001
14 (27.4%) 2 (3.9%)* 0.03
g repeated measures of general linear model.
t with cabergoline and p< 0.001.
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of their macroprolactinemic patients had pituitary
adenomas. Pituitary imaging in the study by Leslie et al. [14]
found that four out of the 55 macroprolactinemic patients
had microadenomas, but none had macroadenomas. In our
study, the patients with hyperprolactinemia all received
the same imaging studies before PEG precipitation. Macro-
prolactinemic patients had a higher rate of negative
MRI findings than those with true hyperprolactinemia
(pZ 0.029). Furthermore, we did not find any instance of
pituitary macroadenomas in our macroprolactinemic
patients, and only three patients (20%) were found to have
microadenomas. The MRI examinations performed on the
macroprolactinemic group could therefore be considered
unnecessary.
In a study by Alfonso et al. [31], about 40% of patients in
the macroprolactin group were treated with a DA, of which
total prolactinemia was normalized in 28%. The study was
retrospective, however, with only a small number of
patients enrolled and it did not measure macroprolatin
levels. As far as we know, no previous studies have evalu-
ated the therapeutic efficiency of DAs in the treatment of
macroprolactinemia. All of our macroprolactinemic
patients were treated with the same dose of cabergoline
for the same period of time. Before cabergoline treatment,
most of these patients had post-PEG precipitating PRL
levels within the normal range. After treatment, the total
PRL levels of the patients were still not normalized. After
PEG precipitation, this group had no apparent change in
PRL levels.
Macroprolactinemia has been considered a cause of
resistance to DAs [32,33]; therefore misdiagnosis may result
in unnecessary and unhelpful therapy as well as unneces-
sary costs. Conversely, a three-case study [34] reported
that DA treatment decreased the serum levels of both
monomeric PRL and macroprolactin and improved hyper-
prolactinemic symptoms. Our study found DA therapy to be
unnecessary and unhelpful. Spontaneous improvement or
resolution may occur in some patients with macro-
prolactinemia, and may not be related to DA treatment.
One study [30] reported that cost savings could be ach-
ieved through diminished requests for imaging procedures,
a reduced number of DA prescriptions and even cases of
pituitary surgery after routine screening for macro-
prolactin, although de Soa´rez et al. [21] did not come to the
same conclusion. The differences in results might be
because many of the patients in the former study received
some tests outside their institution that were not included
in the total cost. Whether the performance of routine
macroprolactin screening can actually reduce inappro-
priate investigation and reduce costs still requires long-
term study.Conclusion
Although macroprolactinemia was first reported 30 years
ago, few physicians in Taiwan are familiar with it and
believe that it can be evaluated in the same way it is in
patients with hyperprolactinemia. Our method of detection
was confirmed by the gold standard method, gel-filtration
chromatography, and excluded equivocal data. Weconclude that neither clinical nor laboratory features can
be used to reliably differentiate between macro-
prolactinemia and true hyperprolactinemia and that
a misdiagnosis of hyperprolactinemia may lead to inap-
propriate investigation with MRI and unnecessary surgery or
medical treatment with DA. Routine screening for all
hyperprolactinemic sera with PEG may therefore help to
reduce the number of misdiagnoses and instances of
unnecessary treatment. The high prevalence of macro-
prolactinemia in Taiwan makes this a priority. Physicians
here might want to encourage laboratories to make the
measurement of macroprolatin a routine study.
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